Roche Farma, S.A — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Roche Farma, S.A appears in 9 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials9

Recruiting shown1

Roles1

SourceClinicalTrials.gov

Clinical trials

9 shown

Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in SpainNCT06991946 · collaborator · 2025-05-20

RECRUITING

Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung CancerNCT03801304 · collaborator · 2019-01-24

COMPLETED

Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)NCT03829306 · collaborator · 2018-06-12

COMPLETED

Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid ArthritisNCT02087696 · collaborator · 2014-05-01

UNKNOWN

Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal CancerNCT01733628 · collaborator · 2012-10-23

COMPLETED

A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast CancerNCT01598285 · collaborator · 2012-04-18

TERMINATED

Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and MetastasisNCT01377363 · collaborator · 2009-12-11

COMPLETED

Study to Evaluate Markers of Response in Locally Advanced Breast CancerNCT01338753 · collaborator · 2009-10-01

COMPLETED

Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 YearsNCT01433926 · collaborator · 2009-09-01

COMPLETED

Drugs studied in this sponsor's trials

3 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Roche Farma, S.A as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

atezolizumab1

tocilizumab1

vinorelbine1

atezolizumab RxCUI 1792776 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial tocilizumab RxCUI 612865 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial vinorelbine RxCUI 39541 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

collaborator9

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.